Analysts view the absence of severe side effects and lack of...
Analysts view the absence of severe side effects and lack of black box warning on Bristol Myers Squibb's new drug as bullish indicators for its stock, hinting at strong market adoption.
FDA Approves New Bristol Myers Squibb Schizophrenia Drug
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment